凯赛生物
(688065)
| 流通市值：313.45亿 | | | 总市值：387.55亿 |
| 流通股本：5.83亿 | | | 总股本：7.21亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 8,720,310,517.31 | 10,797,271,252.93 | 5,346,793,890.23 | 4,637,141,251.89 |
| 交易性金融资产 | 1,102,641,476.69 | 469,248 | 469,248 | 469,248 |
| 应收票据及应收账款 | 472,556,539.42 | 448,953,194.87 | 347,727,732.12 | 419,078,736.59 |
| 其中：应收票据 | 124,115,812.78 | 120,893,965.98 | 100,506,300.11 | 105,550,077.81 |
| 应收账款 | 348,440,726.64 | 328,059,228.89 | 247,221,432.01 | 313,528,658.78 |
| 应收款项融资 | 88,047,804.47 | 67,093,533.11 | 112,148,733.04 | 73,009,084.35 |
| 预付款项 | 108,577,399.82 | 124,326,264.47 | 65,570,949.14 | 82,564,799.49 |
| 其他应收款合计 | 4,659,625.03 | 10,571,470.34 | 10,558,096.29 | 6,562,450.97 |
| 存货 | 1,162,077,938.27 | 1,163,511,149.57 | 1,180,528,263.33 | 1,273,811,937.54 |
| 其他流动资产 | 352,780,288.27 | 335,602,321.99 | 323,117,484.63 | 319,726,843.14 |
| 流动资产合计 | 12,011,651,589.28 | 12,947,798,435.28 | 7,386,914,396.78 | 6,812,364,351.97 |
| 非流动资产: | | | | |
| 长期股权投资 | 153,249,731.62 | 156,664,427.75 | 133,780,523.31 | 137,716,005.08 |
| 固定资产 | 3,759,761,042.1 | 3,830,552,090.06 | 3,899,270,702.9 | 3,953,094,508.92 |
| 在建工程 | 6,146,630,850.8 | 6,016,989,430.65 | 5,949,278,195.16 | 5,782,495,722.36 |
| 无形资产 | 690,142,932.51 | 692,966,132.13 | 685,040,195.02 | 689,208,045.35 |
| 长期待摊费用 | 4,585,548.74 | 5,730,080.14 | 6,422,894.92 | 7,107,279.92 |
| 递延所得税资产 | 239,331,623.18 | 220,610,897.17 | 210,367,738.04 | 177,173,395.86 |
| 其他非流动资产 | 815,829,349.52 | 818,556,910 | 750,402,703.51 | 770,876,693.27 |
| 非流动资产合计 | 11,809,531,078.47 | 11,742,069,967.9 | 11,634,562,952.86 | 11,517,671,650.76 |
| 资产总计 | 23,821,182,667.75 | 24,689,868,403.18 | 19,021,477,349.64 | 18,330,036,002.73 |
| 流动负债: | | | | |
| 短期借款 | 50,384,874.4 | 640,110,503.32 | 1,246,911,528.77 | 691,282,735.14 |
| 应付票据及应付账款 | 1,350,425,010.24 | 1,369,518,721.68 | 1,440,649,689.49 | 1,492,526,872.41 |
| 应付账款 | 1,350,425,010.24 | 1,369,518,721.68 | 1,440,649,689.49 | 1,492,526,872.41 |
| 预收款项 | - | 1,016,536.3 | 2,519,337.16 | 4,030,939.45 |
| 合同负债 | 36,242,732.82 | 36,608,534.69 | 35,807,868.01 | 26,550,628.45 |
| 应付职工薪酬 | 13,109,665.17 | 8,309,395.88 | 21,588,633.62 | 16,514,754.07 |
| 应交税费 | 45,748,095.88 | 43,853,317.91 | 42,848,168.83 | 34,038,786.47 |
| 其他应付款合计 | 363,608,801.11 | 62,028,000.44 | 85,935,770.46 | 70,959,925.46 |
| 应付股利 | 288,411,051.6 | 831,600 | 831,600 | 831,600 |
| 一年内到期的非流动负债 | 11,911,200.98 | 372,323,700.92 | 37,173,778.49 | 34,749,967.25 |
| 其他流动负债 | 4,711,555.27 | 4,727,173.75 | 4,420,771.2 | 3,451,581.7 |
| 流动负债合计 | 1,876,141,935.87 | 2,538,495,884.89 | 2,917,855,546.03 | 2,374,106,190.4 |
| 非流动负债: | | | | |
| 长期借款 | 492,684,716.92 | 623,310,222.65 | 613,263,211.89 | 572,015,398.4 |
| 递延收益 | 377,240,955.59 | 382,746,594.45 | 389,286,381.99 | 394,730,163.78 |
| 递延所得税负债 | 325,834.31 | - | - | - |
| 非流动负债合计 | 870,251,506.82 | 1,006,056,817.1 | 1,002,549,593.88 | 966,745,562.18 |
| 负债合计 | 2,746,393,442.69 | 3,544,552,701.99 | 3,920,405,139.91 | 3,340,851,752.58 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 721,289,794 | 721,289,794 | 583,378,039 | 583,378,039 |
| 资本公积 | 14,300,235,186.22 | 14,298,750,767.2 | 8,520,453,109.55 | 8,530,318,457.92 |
| 减:库存股 | 155,630,224.62 | 155,127,897.6 | 155,127,897.6 | 145,126,101.03 |
| 其他综合收益 | 2,200,999.71 | 2,027,807.66 | -1,834,670.14 | 3,868,949.34 |
| 专项储备 | 17,856,739.44 | 14,397,311.03 | 14,609,585.49 | 12,575,035.83 |
| 盈余公积 | 238,968,963.77 | 238,968,963.77 | 238,968,963.77 | 98,416,146.86 |
| 未分配利润 | 2,327,645,963.86 | 2,443,508,478.75 | 2,306,558,365.18 | 2,303,326,680.95 |
| 归属于母公司股东权益合计 | 17,452,567,422.38 | 17,563,815,224.81 | 11,507,005,495.25 | 11,386,757,208.87 |
| 少数股东权益 | 3,622,221,802.68 | 3,581,500,476.38 | 3,594,066,714.48 | 3,602,427,041.28 |
| 股东权益合计 | 21,074,789,225.06 | 21,145,315,701.19 | 15,101,072,209.73 | 14,989,184,250.15 |
| 负债和股东权益合计 | 23,821,182,667.75 | 24,689,868,403.18 | 19,021,477,349.64 | 18,330,036,002.73 |
| 公告日期 | 2025-08-16 | 2025-04-30 | 2025-04-22 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |